
Immuno Oncology Diagnosis Market Expected To Witness Steady 10% CAGR Amid Expanding Industry Applications

The Business Research Company's Immuno Oncology Diagnosis Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035



Immuno Oncology Diagnosis Market Trends

The Business Research Company
The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, September 21, 2026 /EINPresswire.com/ -- A closer look at the immuno-oncology diagnosis market reveals a sector experiencing rapid expansion due to advancements in cancer detection and treatment methods. With rising cancer cases worldwide and innovative diagnostic technologies emerging, this market is set to undergo significant growth in the coming years. Let's explore the current market size, key drivers, regional outlook, and the factors propelling this expansion.

Projected Market Size and Growth Outlook in the Immuno Oncology Diagnosis Market

The immuno-oncology diagnosis market has seen substantial growth in recent years and is expected to continue this trajectory. It is projected to increase from $13.8 billion in 2025 to $15.15 billion in 2026, marking a compound annual growth rate (CAGR) of 9.7%. This growth reflects rising global cancer prevalence, greater use of targeted therapies, the expansion of hospital diagnostic labs, broader adoption of immunohistochemistry in oncology, and advancements in biomarker discovery technologies.

Download a free sample of the immuno oncology diagnosis market report: https://www.thebusinessresearchcompany.com/sample_request?id=33228154&type=smp&nam

e=Immuno%20Oncology%20Diagnosis%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=paid&utm_campaign=Sep_PR

Looking further ahead, the market is anticipated to reach $22.16 billion by 2030, growing at a CAGR of 10.0%. This surge is fueled by the demand for personalized cancer immunotherapies, the growth of liquid biopsy and non-invasive diagnostic methods, increasing adoption of AI-driven diagnostic platforms, advances in precision medicine and companion diagnostics, and expanding investments in oncology research and clinical trials. Key emerging trends include liquid biopsy-based assays for early cancer detection and monitoring, multiplex immune profiling technologies to characterize tumor microenvironments, companion diagnostic kits tailored for selecting cancer immunotherapy, high-sensitivity flow cytometry for immune cell analysis to aid cancer stratification, and AI-powered digital pathology software for interpreting immuno-oncology biomarkers.

Understanding the Role of Immuno-Oncology Diagnosis
Immuno-oncology diagnosis involves identifying and analyzing cancer-related biomarkers and immune responses to better comprehend the interaction between tumors and the immune system. This approach aids in accurately diagnosing cancers, understanding their unique characteristics, and guiding treatment decisions. It plays a critical role in stratifying patients, optimizing therapy choices, and tracking treatment responses, which collectively enhance overall cancer care and outcomes.

View the full immuno oncology diagnosis market report:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-diagnosis-market-report?utm_source=EINPresswire&utm_medium=paid&utm_campaign=Sep_PR

Primary Factors Driving Growth in the Immuno Oncology Diagnosis Market
One of the main forces behind the market's expansion is the rising prevalence of cancer globally. Cancer, characterized by uncontrolled cell growth and the ability to invade tissues and spread, disrupts normal bodily functions. The increasing incidence is closely linked to the aging population, as genetic mutations and cellular damage accumulate with age, significantly raising cancer risk. Immuno-oncology diagnostics support effective cancer treatment by enabling biomarker detection, immune profiling, and precision testing essential for personalized therapies, thereby improving treatment success and clinical decisions.

Supporting this, in February 2024, the World Health Organization reported projections indicating that by 2050, over 35 million new cancer cases will be diagnosed—a 77% increase compared to around 20 million cases in 2022. This sharp rise in cancer cases worldwide acts as a major catalyst for the growth of the immuno-oncology diagnosis market.

Regional Market Shares and Growth Forecasts
In terms of geographical market presence, North America held the largest share of the immuno-oncology diagnosis market in 2025. Meanwhile, the Asia-Pacific region is expected to experience

the fastest growth during the forecast period. The market analysis covers key regions, including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a broad perspective on global trends and opportunities.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
email us here
Visit us on social media:
LinkedIn
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/943257054

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.